openPR Logo
Press release

Investigation announced for Long-Term Investors in Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)

02-19-2021 05:05 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) shares.

An investigation on behalf of current long term investors in Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) shares.

An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Intercept Pharmaceuticals, Inc..

Investors who are current long term investors in Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for investors in (NASDAQ: ICPT stocks follows a lawsuit filed against Intercept Pharmaceuticals, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: ICPT stocks, concerns whether certain Intercept Pharmaceuticals, Inc. directors are liable in connection with the allegations made in that lawsuit.

The plaintiff alleges that, the Defendants made false and/or misleading statements and/or failed to disclose that the Defendants downplayed the true scope and severity of safety concerns associated with Ocaliva’s use in treating PBC, that the foregoing increased the likelihood of an FDA investigation into Ocaliva’s development, thereby jeopardizing Ocaliva’s continued marketability and the sustainability of its sales, that any purported benefits associated with OCA’s efficacy in treating NASH were outweighed by the risks of its use, that as a result, the FDA was unlikely to approve the Company’s NDA for OCA in treating patients with liver fibrosis due to NASH, and that as a result of all the foregoing, the Company’s public statements were materially false and misleading at all relevant times.

Those who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) here

News-ID: 2245163 • Views:

More Releases from Shareholders Foundation

Lawsuit filed for Investors who lost money with shares of Spirit Aviation Holdings, Inc. (OTC: FLYYQ)
Lawsuit filed for Investors who lost money with shares of Spirit Aviation Holdin …
An investor, who purchased shares of Spirit Aviation Holdings, Inc. (OTC: FLYYQ), filed a lawsuit over alleged violations of Federal Securities Laws by Spirit Aviation Holdings, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased a significant amount of shares of Spirit Aviation Holdings, Inc. (OTC: FLYYQ) between May 28, 2025 and August 29, 2025, have certain options and for certain investors are short and strict deadlines
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly NASDAQ: SINA)
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made. If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: FLR) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp. (NYSE: SOC)
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp. Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in

All 5 Releases


More Releases for Intercept

Sales Intercept Launches to Help Any Website Drive Conversions with High-Impact …
Buffalo, NY - June 2025 - Sales Intercept, a new video engagement platform, officially launches this week to help websites of all kinds capture attention, reduce bounce rates, and convert more visitors. With a simple one-line embed, Sales Intercept brings short-form, social-style video interactions to websites-creating more compelling experiences right where action happens. Whether you're showcasing services, generating leads and sales, or building a subscriber base, Sales Intercept makes it easy
Legal Intercept System Market Is Booming Worldwide | Atos, SS8 Networks
The latest study released on the Global Legal Intercept System Market by HTF MI evaluates market size, trend, and forecast to 2030. The Legal Intercept System market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors. Key
Ocaliva Market Significantly Stepping towards the Success Till 2027| Intercept P …
Obeticholic acid (OCA) is a semi-synthetic bile acid analogue with the molecular structure 6-ethyl-chenodeoxycholic acid, which is sold under the brand name Ocaliva. It is prescribed for the treatment of primary biliary cholangitis. Outside of Japan and China, where it is licenced to Dainippon Sumitomo Pharma, Intercept Pharmaceuticals Inc. holds the worldwide rights to develop OCA. In 2020, the global Ocaliva market size was US$ XX million and it is
Lawsuit filed for Investors in shares of Intercept Pharmaceuticals, Inc. (NASDAQ …
An investor, who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), filed a lawsuit over alleged violations of Federal Securities Laws by Intercept Pharmaceuticals, Inc. Investors who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) have certain options and for certain investors are short and strict deadlines running. Deadline: January 4, 2021. NASDAQ: ICPT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. New York based
Investigation announced for Investors in shares of Intercept Pharmaceuticals, In …
An investigation was announced over potential securities laws violations by Intercept Pharmaceuticals, Inc. in connection with certain financial statements. Investors who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Intercept Pharmaceuticals, Inc. regarding its business, its prospects and its operations were
Submarine Active Intercept and Ranging System Market to Witness Robust Expansion …
LP INFORMATION offers a latest published report on Submarine Active Intercept and Ranging System Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. According to this study, over the next five years the Submarine Active Intercept and Ranging System market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024,